ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Cardiology · JAMA Cardiol · 2026-10-01

Post hoc analysis of HELIOS-B (548 patients with ATTR cardiomyopathy): right ventricular free wall strain was abnormal in 85% and independently predicted death and cardiovascular events. Vutrisiran stabilised it over 30 months versus placebo.

Secondary analysisn = 548
Jering et al. Right Ventricular Function, Clinical Outcomes, and Effect of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: Secondary Analysis of the HELIOS-B Randomized Clinical Trial
Cardiology · JAMA Cardiol · 2026-10-01

Post hoc analysis of HELIOS-B in 644 patients with ATTR cardiomyopathy: worse LA reservoir strain predicted death or cardiovascular events (HR 1.37 per 5% worsening), but LA volume did not. Vutrisiran vs placebo lessened LA strain decline at 30 months (+1.2%).

Secondary analysisn = 644
Jering et al. Left Atrial Structure and Function, Clinical Outcomes, and Efficacy of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: A Secondary Analysis of the HELIOS-B Randomized Clinical Trial

Sign in to react

Enter your email and we send a one-time link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.